Seyed Qaderi and Hans de Wilt together with the department of Surgical Oncology developed and implemented a new patient centered follow up schedule for colorectal cancer survivors.After treatment, colorectal cancer patients remain under surveillance in the hospital for at least 5 years. This is performed according to the national guidelines.
The purpose of these appointments is to screen for symptoms and explore patient wellbeing, and to detect metastases or recurrent disease as early as possible.
Research demonstrates that periodic outpatient clinic visits are not always useful. It leads to long waiting times and it can lead to more (unnecessary) treatments, anxiety among patients and higher healthcare costs without improving patient survival.
Patient organizations and health professionals call for new patient-oriented follow up schedules. In these new schemes emphasis should be on quality of life, attention to the consequences of operative interventions on daily life, psychosocial wellbeing.
More involvement of patients in decision making and follow up improves the emotional and social well-being of patients and gives the patient more autonomy and (self-) confidence.
The follow up policy of colorectal cancer patients treated at Radboudumc has changed. After being followed, undergoing the necessary tests in the first year, patients do not longer have to come to the hospital for the results of the tests hereafter. The results will be made available through our electronic mijnRadboud platform in a patient-friendly manner. When experiencing symptoms, having questions, or noticing abnormal test results, patients are advised to call our nurse practitioner and when necessary, telephone, video-chat, or a physical clinical visit will be planned.
With adequate patient training and written information and instructions on what to do and when to do (self management), we aim at increasing patient involvement and satisfaction during bowel cancer follow up!
More information can be found (in Dutch): www.radboudumc.nl/darmkanker
Seyed Qaderi and Hans de Wilt are both members of theme Tumors of digestive tract.
Related news items
Dutch Cancer Society Grant received by Annemiek van Spriel and Laia Querol-Cano23 September 2020
Annemiek van Spriel and Laia Querol-Cano received a Dutch Cancer Society Grant of 700K euros to study the cancer cell surface in immunotherapy.read more
Tumor cells stimulate lipid biosynthesis in macrophages23 September 2020
RIMLS researchers wrote in the Journal for ImmunoTherapy of Cancer that improved lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics.read more
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genomics of Neurodevelopmental Disorders17 September 2020
Annette Schenck has been appointed professor of Translational Genomics of Neurodevelopmental Disorders. with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more